Study to investigate at-home Covid treatments
The study, which is recruiting now, will quickly assess the effectiveness of a range of purpose-designed antivirals.
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A first-of-its-kind clinical trial will investigate new at-home coronavirus oral antiviral treatments.
The study, which is recruiting now, will quickly assess the effectiveness of a range of purpose-designed Covid-19 antivirals.
The new drugs are intended for use in the early stages of infection by people with the virus who are at higher risk of complications from the disease.
The Platform Adaptive trial of NOvel antiviRals for eArly treatMent of covid-19 In the Community (PANORAMIC), is run by the University of Oxford in collaboration with GP hubs.
The UK Antiviral Taskforce has selected the treatments to be tested, and the first to be investigated will be molnupiravir, a Covid antiviral pill already licensed by the the Medicines and Healthcare products Regulatory Agency (MHRA).
People can join the study if they have tested positive for the virus, are within five days from the onset of symptoms – and are aged 50 and over.
Or if they are between 18 to 49 years with underlying health conditions that make them clinically more vulnerable. All participants should have recorded a positive PCR test within the past seven days.
The study will enrol 10,600 volunteers for each arm of the study.
To enable the benefit of the treatment to be compared against standard care, half of them will be randomly allocated to receive the antiviral treatment plus standard care.
The other half will receive standard care alone.
Results from the national study will enable the NHS to better plan how to make Covid-19 antivirals available for those who would benefit from them the most.
Eddie Gray, chairman of UK Antivirals Taskforce, said: “We want to ensure that a wide number of people are conscious and aware that if they get symptoms and a positive test, they qualify and for them to move quickly into that system.
“I think if they can do that, then there’s an awful lot of benefit to be gained both for those individual patients and for the UK healthcare system.”
He added: “I think it gives us a real mechanism for managing patients in what is an extremely high pressure time for frontline staff in the National Health Service.
“But for us to do that, we need the active engagement of the potential patients.”